Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B trial of fosciclopirox in newly diagnosed and recurrent urothelial cancer patients scheduled for transurethral resection of bladder tumors

Next Previous
Trial Profile

A Phase 1B trial of fosciclopirox in newly diagnosed and recurrent urothelial cancer patients scheduled for transurethral resection of bladder tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosciclopirox (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jul 2021 New trial record
  • 29 Jun 2021 According to a CicloMed media release, the trial is being conducted at The University of Kansas Cancer Center under the leadership of John A. Taylor III.
  • 29 Jun 2021 According to CicloMed media release in September 2020, the company was awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI), enabling the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top